Merck announced that the FDA has approved Noxafil (posaconazole) delayed-release tablets, a new formulation of this antifungal agent.

Noxafil is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients >13 years old who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia (low white blood cell counts) from chemotherapy.

RELATED: Infectious Disease Resource Center

Posaconazole is an antifungal that blocks the synthesis of ergosterol through the inhibition of lanosterol 14α-demethylase, a CYP450 dependent enzyme that is responsible for the conversion of lanosterol to ergosterol in the fungal cell membrane. 

This results in an accumulation of methylated sterol precursors and a depletion of ergosterol within the cell membrane thus weakening the structure and function of the fungal cell membrane.

Noxafil delayed-release tablets will be available in a 100mg strength in 60-count bottles. Noxafil oral suspension is currently available in a 40mg/mL strength in 4 ounce bottles.

For more information call (800) 672-6372 or visit